Show simple item record

dc.contributor.authorAndrade, Susan E.
dc.contributor.authorReichman, Marsha
dc.contributor.authorMott, Katrina
dc.contributor.authorPitts, Marilyn
dc.contributor.authorKieswetter, Caren
dc.contributor.authorDinatale, Miriam
dc.contributor.authorStone, Marc B.
dc.contributor.authorPopovic, Jennifer
dc.contributor.authorHaffenreffer, Katherine
dc.contributor.authorToh, Sengwee
dc.date2022-08-11T08:08:20.000
dc.date.accessioned2022-08-23T15:51:20Z
dc.date.available2022-08-23T15:51:20Z
dc.date.issued2016-12-01
dc.date.submitted2017-02-13
dc.identifier.citationArch Womens Ment Health. 2016 Dec;19(6):969-977. Epub 2016 May 13. <a href="https://doi.org/10.1007/s00737-016-0637-1">Link to article on publisher's site</a>
dc.identifier.issn1434-1816 (Linking)
dc.identifier.doi10.1007/s00737-016-0637-1
dc.identifier.pmid27178125
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28874
dc.description.abstractThis study was conducted in order to assess the prevalence of use of selective serotonin reuptake inhibitors (SSRIs) among pregnant women delivering a liveborn infant in the USA. A retrospective study was conducted using the automated databases of 15 health-care systems participating in the Mini-Sentinel program. Diagnosis and procedure codes were used to identify women ages 10 to 54 years delivering a liveborn infant between April 2001 and December 2013. A comparison group of age- and date-matched women without live births was identified. The frequency of use of SSRIs was identified from outpatient dispensing data. Among the 1,895,519 liveborn deliveries, 113,689 women (6.0 %) were exposed to an SSRI during pregnancy during the period 2001-2013; 5.4 % were exposed to an SSRI during 2013. During the corresponding time period, 10.5 % of the age- and date-matched cohort of women without live births was exposed to an SSRI, with 10.1 % exposed to an SSRI during 2013. The most common agents dispensed during pregnancy were sertraline (n = 48,678), fluoxetine (n = 28,983), and citalopram (n = 20,591). Among those women exposed to an SSRI during pregnancy, 53.8 % had a diagnosis of depression and 37.3 % had a diagnosis of an anxiety disorder during pregnancy or within 180 days prior to pregnancy. Our finding that 6 % of women with live births were prescribed SSRIs during pregnancy highlights the importance of understanding the differential effects of these medications and other therapeutic options on the developing fetus and on the pregnant women.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27178125&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1007/s00737-016-0637-1
dc.subjectPregnancy
dc.subjectPrevalence
dc.subjectSelective serotonin reuptake inhibitors
dc.subjectMaternal and Child Health
dc.subjectPsychiatry and Psychology
dc.subjectWomen's Health
dc.titleUse of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program
dc.typeJournal Article
dc.source.journaltitleArchives of women's mental health
dc.source.volume19
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1108
dc.identifier.contextkey9679929
html.description.abstract<p>This study was conducted in order to assess the prevalence of use of selective serotonin reuptake inhibitors (SSRIs) among pregnant women delivering a liveborn infant in the USA. A retrospective study was conducted using the automated databases of 15 health-care systems participating in the Mini-Sentinel program. Diagnosis and procedure codes were used to identify women ages 10 to 54 years delivering a liveborn infant between April 2001 and December 2013. A comparison group of age- and date-matched women without live births was identified. The frequency of use of SSRIs was identified from outpatient dispensing data. Among the 1,895,519 liveborn deliveries, 113,689 women (6.0 %) were exposed to an SSRI during pregnancy during the period 2001-2013; 5.4 % were exposed to an SSRI during 2013. During the corresponding time period, 10.5 % of the age- and date-matched cohort of women without live births was exposed to an SSRI, with 10.1 % exposed to an SSRI during 2013. The most common agents dispensed during pregnancy were sertraline (n = 48,678), fluoxetine (n = 28,983), and citalopram (n = 20,591). Among those women exposed to an SSRI during pregnancy, 53.8 % had a diagnosis of depression and 37.3 % had a diagnosis of an anxiety disorder during pregnancy or within 180 days prior to pregnancy. Our finding that 6 % of women with live births were prescribed SSRIs during pregnancy highlights the importance of understanding the differential effects of these medications and other therapeutic options on the developing fetus and on the pregnant women.</p>
dc.identifier.submissionpathfaculty_pubs/1108
dc.contributor.departmentDepartment of Medicine
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages969-977


This item appears in the following Collection(s)

Show simple item record